Prospective and randomized study on the efficacy of novel hypoglycemic type 2 diabetes agent ipragliflozin to serum glycemic control and cardiovascular risk factors
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000014422
- Lead Sponsor
- Fukui-ken Saiseikai Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) With receiving insulin therapy 2) With a history of ischemic heart disease (angina pectoris, myocardial infarction) and ischemic stroke 3) Serum Creatinine >= 1.2 mg/dL 4) Fasting serum triglycerides levels >= 400 mg/dL 5) HbA1c was changed 2% or more within 3 months 6) With unconscious thirst (impossible self-judgement water intake) 7) With contraindication for ipragliflozin a) History of hypersensitivity to ipragliflozin b) Severe ketosis, diabetic or precoma c) Severe infection, pre or post surgery, and severe trauma 8) Considered as inadequate by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method